TNFRSF9 and cancer: The broad range of 4-1BB expression on multiple cell types makes this receptor a dual-edged sword in the fight against cancer as 4-1BB agonists might elicit strong antitumor responses from a myriad of cell types, however, sometimes at the cost of off-target immune pathology [72].